Ankle-Brachial Index and Peripheral Arterial Disease

Patients with peripheral arterial disease including those with intermittent claudication have a high risk for cardiovascular and cerebrovascular morbidity and mortality. The outcome of patients with intermittent claudication is less limited by local complications in the leg than by the systemic complications of coronary and cerebral vessels. About 30 % of these patients will die within 5 years, three-quarters of them due to vascular events. Analyses using data of the KORA Study 2004/2005 (F3), a follow-up examination of the participants of the MONICA Survey 1994/95 (S3), will try to identify biochemical as well as genetic risk factors for peripheral arterial disease. The anti-atherogenic apolipoprotein A-IV will be one of our candidates of interest.

[1]  F. Kronenberg,et al.  Decrease of plasma apolipoprotein A-IV during weight reduction in obese adolescents on a low fat diet , 2004, International Journal of Obesity.

[2]  J. Allenberg,et al.  High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. , 2004, Atherosclerosis.

[3]  S. Woods,et al.  Peripheral signals in the control of satiety and hunger , 2003, Current opinion in clinical nutrition and metabolic care.

[4]  F. Kronenberg,et al.  Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls Published, JLR Papers in Press, June 1, 2003. DOI 10.1194/jlr.M300060-JLR200 , 2003, Journal of Lipid Research.

[5]  Wai-Man R. Wong,et al.  Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels , 2003, Circulation research.

[6]  M. Hutz,et al.  Further evidence for the association between obesity-related traits and the apolipoprotein A-IV gene , 2003, International Journal of Obesity.

[7]  B. Jönsson,et al.  Ankle-brachial index and mortality in a cohort of questionnaire recorded leg pain on walking. , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[8]  J. Murabito,et al.  Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. , 2002, American heart journal.

[9]  J. Ribalta,et al.  Antioxidative and Antiatherosclerotic Effects of Human Apolipoprotein A-IV in Apolipoprotein E-Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Webster,et al.  Outcome events in patients with claudication: a 15-year study in 2777 patients. , 2001, Journal of vascular surgery.

[11]  F. Greenway,et al.  Common apolipoprotein A-IV variants are associated with differences in body mass index levels and percentage body fat , 2000, International Journal of Obesity.

[12]  Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Section D: chronic critical limb ischaemia. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[13]  K. Jaeger,et al.  Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. , 1999, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[14]  L. Bouter,et al.  Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Tso,et al.  Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. , 1998, American journal of physiology. Heart and circulatory physiology.

[16]  Arno W. Hoes,et al.  Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R B D'Agostino,et al.  Intermittent claudication. A risk profile from The Framingham Heart Study. , 1997, Circulation.

[18]  J. Qiao,et al.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. , 1997, The Journal of clinical investigation.

[19]  P. Denéfle,et al.  Protection Against Atherogenesis in Mice Mediated by Human Apolipoprotein A-IV , 1996, Science.

[20]  A. von Eckardstein,et al.  Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[21]  R. Hamman,et al.  Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. , 1995, Circulation.

[22]  C Ahn,et al.  Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. , 1994, The American journal of cardiology.

[23]  P. Gambert,et al.  Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. , 1994, Journal of lipid research.

[24]  S. Bovard-Houppermans.  [Human apolipoprotein A-IV]. , 1994, Annales de biologie clinique.

[25]  J. Fruchart,et al.  Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  F. Fowkes,et al.  The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. , 1992, Journal of clinical epidemiology.

[27]  J. Fruchart,et al.  Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. , 1990, The Journal of biological chemistry.

[28]  I. Goldberg,et al.  Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.

[29]  R. Prescott,et al.  Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. , 1988, Journal of epidemiology and community health.

[30]  M. Lefevre,et al.  The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. , 1986, Biochimica et biophysica acta.

[31]  J. Albers,et al.  Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma. , 1985, Biochimica et biophysica acta.

[32]  G. Utermann,et al.  Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. , 1985, The Journal of biological chemistry.

[33]  N. Hertzer,et al.  Coronary Artery Disease in Peripheral Vascular Patients: A Classification of 1000 Coronary Angiograms and Results of Surgical Management , 1984, Annals of surgery.

[34]  R. Greenhalgh,et al.  The detection and progression of asymptomatic peripheral arterial disease , 1983, The British journal of surgery.

[35]  S. A. Saleh,et al.  Aortoiliac occlusive disease: factors influencing survival and function following reconstructive operation over a twenty-five-year period. , 1981, Surgery.

[36]  O Munck,et al.  Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. , 1981, Journal of chronic diseases.

[37]  F. Sebening,et al.  [Coronary artery disease]. , 1980, Verhandlungen der Deutschen Gesellschaft fur Herz- und Kreislaufforschung.

[38]  J. Mann,et al.  Intermittent claudication: prevalence and risk factors. , 1978, British medical journal.

[39]  J. Ross,et al.  BLOOD PRESSURE MEASUREMENT WITH DOPPLER ULTRASONIC FLOWMETER , 1972, Journal of applied physiology.

[40]  H F Stegall,et al.  Indirect measurment of arterial blood pressure by Doppler ultrasonic sphygmomanometry. , 1968, Journal of applied physiology.

[41]  S A Carter,et al.  Indirect Systolic Pressures and Pulse Waves in Arterial Occlusive Disease of the Lower Extremities , 1968, Circulation.